Abiomed Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abiomed in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Abiomed stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ABMD, but not buy additional shares or sell existing shares.
View analyst ratings for Abiomed or view top-rated stocks.

Wall Street analysts have given Abiomed a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Abiomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Abiomed is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Abiomed.

Abiomed will be holding an earnings conference call on Thursday, August 5th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "5929017".

Abiomed, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Wednesday, April, 28th. The medical equipment provider reported $1.24 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.10 by $0.14. The medical equipment provider earned $241.30 million during the quarter, compared to analysts' expectations of $231.13 million. Abiomed had a net margin of 26.61% and a trailing twelve-month return on equity of 14.99%. The business's revenue for the quarter was up 16.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 earnings per share.
View Abiomed's earnings history.

Abiomed's stock was trading at $151.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABMD stock has increased by 116.1% and is now trading at $326.52.
View which stocks have been most impacted by COVID-19.

Abiomed updated its FY 2022 earnings guidance on Thursday, May, 6th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $990 M-$1.03 billion, compared to the consensus revenue estimate of $998.13 million.

4 equities research analysts have issued twelve-month price objectives for Abiomed's stock. Their forecasts range from $245.00 to $425.00. On average, they anticipate Abiomed's share price to reach $341.25 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Abiomed or view top-rated stocks among Wall Street analysts.

96 employees have rated Abiomed CEO Michael R. Minogue on Glassdoor.com. Michael R. Minogue has an approval rating of 72% among Abiomed's employees.

Some companies that are related to Abiomed include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), Hologic (HOLX), STERIS (STE), Insulet (PODD) and Teleflex (TFX).
View all of ABMD's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abiomed investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Align Technology (ALGN), Arista Networks (ANET), Intuitive Surgical (ISRG), Square (SQ), Netflix (NFLX), Adobe (ADBE) and salesforce.com (CRM).

Abiomed trades on the NASDAQ under the ticker symbol "ABMD."

Abiomed's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (8.01%), Alliancebernstein L.P. (1.85%), New York State Common Retirement Fund (0.54%), Villere ST Denis J & Co. LLC (0.46%), Marathon Asset Management LLP (0.35%) and Chicago Capital LLC (0.34%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue and Paul Thomas.
View institutional ownership trends for Abiomed.

ABMD stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, Victory Capital Management Inc., Scout Investments Inc., Sumitomo Mitsui Trust Holdings Inc., Beacon Investment Advisory Services Inc., PGGM Investments, Zurcher Kantonalbank Zurich Cantonalbank , and Advisors Asset Management Inc.. Company insiders that have sold Abiomed company stock in the last year include Andrew J Greenfield, Joseph Riccelli, Magdalena Yesil, Martin P Sutter, Michael R Minogue, and Paul Thomas.
View insider buying and selling activity for Abiomed or view top insider-selling stocks.

ABMD stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Marathon Asset Management LLP, Alliancebernstein L.P., State of Alaska Department of Revenue, Oregon Public Employees Retirement Fund, Chicago Capital LLC, Aegon Asset Management UK PLC, and V Wealth Advisors LLC.
View insider buying and selling activity for Abiomed or or view top insider-buying stocks.

Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABMD stock can currently be purchased for approximately $326.52.

Abiomed has a market capitalization of $14.81 billion and generates $847.52 million in revenue each year. The medical equipment provider earns $225.52 million in net income (profit) each year or $4.94 on an earnings per share basis.

Abiomed employs 1,725 workers across the globe.

The following companies are subsidiares of Abiomed: ABD Holding Company, ABIOMED Athlone Ltd, ABIOMED Australia Pte. Ltd, ABIOMED Europe, ABIOMED Japan KK, ABIOMED Limited, ABIOMED R&D, ABIOMED SARL, ABIOMED Singapore Pte. Ltd, AIS GmbH Aachen Innovative Solutions, ECP Entwicklungsgesellschaft mbH, and Impella Cardiosystems.

Abiomed was founded in 1981.

The official website for Abiomed is www.abiomed.com.

Abiomed is headquartered at 22 CHERRY HILL DR, DANVERS MA, 01923.

Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]